Demographic and baseline characteristics for B-cell ALL and T-cell ALL/LL cohorts
| Characteristic . | Childhood B-cell ALL (n = 7) . | Childhood T-cell ALL (n = 24) . | Young adult T-cell ALL (n = 5) . | T-cell LL (n = 10) . |
|---|---|---|---|---|
| Age, median (range), y | 5.0 (4-17) | 10.0 (2-17) | 23.0 (18-25) | 14.5 (5-22) |
| Sex, n (%) | ||||
| Female | 4 (57.1) | 10 (41.7) | 0 | 1 (10.0) |
| Male | 3 (42.9) | 14 (58.3) | 5 (100) | 9 (90.0) |
| Race, n (%) | ||||
| White | 5 (71.4) | 18 (75.0) | 2 (40.0) | 8 (80.0) |
| Asian | 0 | 1 (4.2) | 1 (20.0) | 0 |
| Black/African American | 0 | 0 | 1 (20.0) | 0 |
| American Indian/Alaska Native | 0 | 0 | 1 (20.0) | 0 |
| Not reported | 2 (28.6) | 5 (20.8) | 0 | 2 (20.0) |
| Hispanic/Latino ethnicity, n (%) | 1 (14.3) | 4 (16.7) | 2 (40.0) | 1 (10.0) |
| Time from initial diagnosis to first dose, median (range), y | 2.7 (1.6-4.3) | 2.5 (0.5-6.1) | 0.6 (0.05-5.6) | 0.8 (0.5-6.0) |
| Lines of prior systemic therapy, median (range) | 2.0 (1.0-10.0)∗ | 1.0 (1.0-1.0) | 1.0 (1.0-1.0) | 1.0 (1.0-1.0) |
| Time from last progression of prior systemic therapy to first dose, median (range), d | 15.0 (10.0-112.0) | 8.5 (4.0-23.0) | 7.0 (2.0-26.0) | 11.0 (4.0-25.0) |
| Blast count,† median (range), % | 62.0 (20.0-99.0) | 67.0 (6.7-98.0) | 71.0 (32.4-96.2) | 4.0 (0-65.0) |
| Extramedullary disease, n (%) | 0 | 4 (16.7) | 2 (40.0) | 10 (100) |
| CNS negative at study entry, n (%) | 7 (100) | 20 (83.3) | 3 (60.0) | 8 (80.0) |
| Characteristic . | Childhood B-cell ALL (n = 7) . | Childhood T-cell ALL (n = 24) . | Young adult T-cell ALL (n = 5) . | T-cell LL (n = 10) . |
|---|---|---|---|---|
| Age, median (range), y | 5.0 (4-17) | 10.0 (2-17) | 23.0 (18-25) | 14.5 (5-22) |
| Sex, n (%) | ||||
| Female | 4 (57.1) | 10 (41.7) | 0 | 1 (10.0) |
| Male | 3 (42.9) | 14 (58.3) | 5 (100) | 9 (90.0) |
| Race, n (%) | ||||
| White | 5 (71.4) | 18 (75.0) | 2 (40.0) | 8 (80.0) |
| Asian | 0 | 1 (4.2) | 1 (20.0) | 0 |
| Black/African American | 0 | 0 | 1 (20.0) | 0 |
| American Indian/Alaska Native | 0 | 0 | 1 (20.0) | 0 |
| Not reported | 2 (28.6) | 5 (20.8) | 0 | 2 (20.0) |
| Hispanic/Latino ethnicity, n (%) | 1 (14.3) | 4 (16.7) | 2 (40.0) | 1 (10.0) |
| Time from initial diagnosis to first dose, median (range), y | 2.7 (1.6-4.3) | 2.5 (0.5-6.1) | 0.6 (0.05-5.6) | 0.8 (0.5-6.0) |
| Lines of prior systemic therapy, median (range) | 2.0 (1.0-10.0)∗ | 1.0 (1.0-1.0) | 1.0 (1.0-1.0) | 1.0 (1.0-1.0) |
| Time from last progression of prior systemic therapy to first dose, median (range), d | 15.0 (10.0-112.0) | 8.5 (4.0-23.0) | 7.0 (2.0-26.0) | 11.0 (4.0-25.0) |
| Blast count,† median (range), % | 62.0 (20.0-99.0) | 67.0 (6.7-98.0) | 71.0 (32.4-96.2) | 4.0 (0-65.0) |
| Extramedullary disease, n (%) | 0 | 4 (16.7) | 2 (40.0) | 10 (100) |
| CNS negative at study entry, n (%) | 7 (100) | 20 (83.3) | 3 (60.0) | 8 (80.0) |
CNS, central nervous system.
Two patients in the childhood B-cell ALL cohort were listed in error as receiving only 1 prior systemic therapy. Both patients received >1 prior line of treatment; however, access to data entry was terminated after site closure and subsequent database lock, and the data thus could not be corrected.
Number of tumorous leukemia/lymphoma cells (%) present in the bone marrow as assessed by bone marrow aspirate/biopsy.